Sudarshan Pharma’s proposed USFDA manufacturing plant acquisition: what the asset includes and why it matters
/** Insufficient financial performance data (revenue/EBITDA/PAT, period results) to write a 1300–1500 word investor-style blogpost with factual financial tables. Document is a facility acquisition presentation without financial statements or KPIs. */
Frequently Asked Questions
An API and API-intermediate manufacturing unit described as USFDA-approved, with multiple production blocks and a solvent recovery system.
The presentation states the site is about 40 km from Visakhapatnam Airport and is spread over 14 acres.
It is engaged in manufacturing APIs and API intermediates, and it states it is not manufacturing steroids, penicillin, beta lactam antibiotics, hormones or cytotoxic products.
The presentation states the site was audited and accepted by WHO Geneva in 2024, approved by USFDA (ANDA-217608) in 2024, and approved by ANVISA in 2025.
The presentation lists four operating production blocks with a total capacity of 584 KL, plus a solvent recovery system of 36 KL.
The presentation provides a list of intermediates across multiple therapeutic categories and lists Lamivudine as an API (USP/IP grade).
No. The provided document does not specify transaction value, financing, or projected financial contribution.
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker